Intra-patient variability in adalimumab drug levels within and between cycles in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 45, Issue 8, 2017, Pages 1135-1145

  Ward, M G ^a,b,c   Thwaites, P A ^a   Beswick, L ^b   Hogg, J ^a   Rosella, G ^a   Van Langenberg, D ^b,c   Reynolds, J ^c   Gibson, P R ^a,c   Sparrow, M P ^a,c  

^a ALFRED HOSPITAL   (Australia)

^b EASTERN HEALTH   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CALGRANULIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HARVEY BRADSHAW INDEX; HUMAN; INTRA-PATIENT VARIABILITY; MALE; MINIMUM PLASMA CONCENTRATION; OBSERVATIONAL STUDY; PATIENT IDENTIFICATION; PREDICTION; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SMOKING; STATISTICAL ANALYSIS; SYRINGE; BLOOD; INDIVIDUALITY; METABOLISM; MIDDLE AGED; OBSERVER VARIATION; PROGNOSIS; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; C-REACTIVE PROTEIN; CROHN DISEASE; DRUG MONITORING; FEMALE; HUMANS; INDIVIDUALITY; MALE; MIDDLE AGED; OBSERVER VARIATION; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 85013787029     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13992     Document Type: Article

References (44)

1. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323–33.
2. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232–9.
3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–9.
4. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876–85.
5. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780–7.
6. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462–76.
7. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011; 33: 987–95.
8. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601–8.
9. Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628–40.
10. Steenholdt C, Bendtzen K, Brynskov J, et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis 2016; 22: 1999–2015.
11. Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 2015; 149: 350–2.
12. Colombel J-F, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383–95.
13. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248–54.
14. Steenholdt C, Bendtzen K, Brynskov J, et al. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011; 46: 310–8.
15. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49–54.
16. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014; 63: 1721–7.
17. Paul S, Del Tedesco E, Marotte H, et al. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2013; 19: 2568–76.
18. Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease. J Crohns Colitis 2013; 7: 736–43.
19. Vande Casteele N, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology 2015; 148: 1320–3.
20. Roblin X, Marotte H, Rinaudo M, et al. Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol 2014; 12: 80–2.
21. Chiu Y-L, Rubin DT, Vermeire S, et al. Serum adalimumab concentration and clinical remission in patients with Crohnʼs disease. Inflamm Bowel Dis 2013; 19: 1112–22.
22. Paul S, Moreau AC, Del Tedesco E, et al. Pharmacokinetics of Adalimumab in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2014; 20: 1288–95.
23. Lie MRKL, Peppelenbosch MP, West RL, et al. Adalimumab in Crohn's disease patients: pharmacokinetics in the first 6 months of treatment. Aliment Pharmacol Ther 2014; 40: 1202–8.
24. Van Assche G, Dignass A, Panés J, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010; 4: 7–27.
25. Harvey RF, Bradshaw MJ. Measuring Crohn's disease activity. Lancet 1980; 1: 1134–5.
26. Satsangi J, Silverberg MS, Vermeire S, Colombel J-F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749–53.
27. Vande Casteele N, Gils A. Pharmacokinetics of anti-TNF monoclonal antibodies in inflammatory bowel disease: adding value to current practice. J Clin Pharmacol 2015; 55(Suppl. 3): S39–50.
28. Hendy P, Hart A, Irving P. Anti-TNF drug and antidrug antibody level monitoring in IBD: A practical guide. Frontline Gastroenterol 2016; 7: 122–8.
29. Ternant D, Karmiris K, Vermeire S, et al. Pharmacokinetics of adalimumab in Crohn's disease. Eur J Clin Pharmacol 2015; 71: 1155–7.
30. Ternant D, Ducourau E, Fuzibet P, et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol 2015; 79: 286–97.
31. Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Aliment Pharmacol Ther 2015; 43: 30–51.
32. Brandse JF, Vos LMC, Jansen J, et al. Serum concentration of anti-TNF antibodies, adverse effects and quality of life in patients with inflammatory bowel disease in remission on maintenance treatment. J Crohns Colitis 2015; 9: 973–81.
33. Yarur AJ, Kubiliun MJ, Czul F, et al. Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy. Clin Gastroenterol Hepatol 2015; 13: 1118–24.
34. Dotan I, Ron Y, Yanai H, et al. Patient factors that increase infliximab clearance and shorten half-life in inflammatory bowel disease: a population pharmacokinetic study. Inflamm Bowel Dis 2014; 20: 2247–59.
35. Mazor Y, Almog R, Kopylov U, et al. Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease. Aliment Pharmacol Ther 2014; 40: 620–8.
36. Paulson S, Noertersheuser P, Garimella T, et al. Assessment of relative bioavailability, safety, and tolerability of single doses of adalimumab administered via an autoinjector pen and a prefilled syringe. J Am Acad Dermatol 2007; 56: AB9–AB9.
37. Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009; 65: 1211–28.
38. Bodini G, Giannini EG, Savarino EV, et al. Adalimumab trough levels and response to biological treatment in patients with inflammatory bowel disease: a useful cutoff in clinical practice. Am J Gastroenterol 2015; 110: 472–3.
39. Horne R, Parham R, Driscoll R, et al. Patients’ attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 837–44.
40. Lopez A, Billioud V, Peyrin-Biroulet C, et al. Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review. Inflamm Bowel Dis 2013; 19: 1528–33.
41. Walsham NE, Sherwood RA. Fecal calprotectin in inflammatory bowel disease. Clin Exp Gastroenterol 2016; 9: 21–9.
42. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2009; 105: 162–9.
43. Gecse KB, Brandse JF, van Wilpe S, et al. Impact of disease location on fecal calprotectin levels in Crohn's disease. Scand J Gastroenterol 2015; 50: 841–7.
44. Stawczyk-Eder K, Eder P, Lykowska-Szuber L, et al. Is faecal calprotectin equally useful in all Crohn's disease locations? A prospective, comparative study. Arch Med Sci 2015; 11: 353–61.